Latest by Richard Jefferys
In the search for a cure, multiple clinical trials are investigating whether immune-based approaches can deliver the "kill" in "kick and kill."
A major focus of HIV cure research is on reversing HIV latency -- essentially switching on the latent virus's DNA machinery so that it starts making proteins.
There are a variety of technologies available to accurately quantify the latent HIV reservoir, but each has pros and cons.
As the research effort to develop a safe, effective, broadly accessible HIV cure expands, the issue of how to measure success remains central.
Two recent case reports of temporary HIV remission, first presented at this year's CROI and IAS conferences, have now been published in the open access journal PLoS Medicine.
New research supports the theory that HIV latency occurs when HIV infects a CD4 T cell that is in the process of transitioning from an activated state to a resting state.
Researchers are flipping the idea of latency reversal on its head. Their approach -- which they have dubbed block and lock -- involves trying to imprison latent HIV in a way that prevents it from ever reactivating.
Researchers estimated a total body burden of as many as seven million cells expressing HIV RNA at any given time in tissues, despite viral load suppression to undetectable levels in the blood.
Effects of the Anti-Inflammatory Antibody Canakinumab on Heart Disease and Cancer: Implications for HIV?
New study results prompt the question of whether canakinumab or other anti-inflammatories could have salutary clinical effects in HIV-positive people.
Many approaches being pursued as cancer therapeutics are also being studied in the context of HIV cure research, including immune checkpoint inhibitors, cytokine therapies, genetically modified chimeric antigen receptor (CAR) T cells and other gene t...